Core Viewpoint - Disc Medicine, Inc. has announced an upsized underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $225.5 million to fund research and clinical development of its product candidates and for general corporate purposes [1][2]. Group 1: Offering Details - Disc is selling 3,918,182 shares of common stock at an offering price of $55.00 per share and pre-funded warrants to purchase 181,818 shares at $54.9999 each [1]. - The total gross proceeds from the offering are expected to be around $225.5 million, before deducting underwriting discounts and commissions [1]. - Underwriters have a 30-day option to purchase up to an additional $33.825 million of shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund research and clinical development of current or additional product candidates, support commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and for working capital and other general corporate purposes [2]. Group 3: Underwriters - Jefferies, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering, while BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. are co-managers [3]. Group 4: Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases, targeting fundamental biological pathways of red blood cell biology [6].

Core Viewpoint - Disc Medicine, Inc. has initiated an underwritten offering of $200 million in common stock, with an additional option for underwriters to purchase up to $30 million more, aimed at funding research and clinical development for hematologic diseases [1][2]. Group 1: Offering Details - The offering consists of $200 million in common stock and pre-funded warrants for certain investors [1]. - Underwriters have a 30-day option to purchase an additional $30 million in shares at the public offering price [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) [2]. - Funds will also support working capital and other general corporate purposes [2]. Group 3: Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases [5]. - The company aims to create innovative therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [5].

Core Viewpoint - Disc Medicine, Inc. has initiated an underwritten offering of $200 million in common stock, with an additional option for underwriters to purchase up to $30 million more, aimed at funding research and clinical development for hematologic diseases [1][2]. Group 1: Offering Details - The offering consists of $200 million in common stock and pre-funded warrants for certain investors [1]. - Underwriters have a 30-day option to purchase an additional $30 million in shares at the public offering price [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) [2]. - Funds will also support working capital and other general corporate purposes [2]. Group 3: Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases [5]. - The company aims to create innovative therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [5].

Core Viewpoint - Disc Medicine, Inc. received positive feedback from the FDA regarding the APOLLO post-marketing confirmatory trial for bitopertin in Erythropoietic Protoporphyria (EPP), marking progress towards potential accelerated approval and eventual full approval of the therapy [1][2][5] Group 1: FDA Interaction and Trial Plans - The FDA interaction is seen as a significant step towards providing a life-altering therapy for EPP patients, with plans to submit a New Drug Application (NDA) in the second half of 2025 [2][5] - The APOLLO trial is set to begin by mid-2025, with sites planned in the US, Canada, Europe, and Australia, and is expected to be well underway by the time of potential accelerated approval [3][5] - The Type C meeting clarified the design of the APOLLO trial, aligning on co-primary endpoints including average monthly time in light without pain and percent change in whole-blood metal-free protoporphyrin IX (PPIX) after six months of treatment [5][6] Group 2: Bitopertin Overview - Bitopertin is an investigational, orally administered inhibitor of glycine transporter 1 (GlyT1), aimed at modulating heme biosynthesis and potentially serving as the first disease-modifying therapy for hematologic diseases [4][8] - The drug has undergone multiple clinical trials, including the Phase 2 BEACON and AURORA trials, focusing on its efficacy in treating EPP [4][5] Group 3: Erythropoietic Protoporphyria (EPP) Context - EPP is a rare and debilitating disease caused by mutations affecting heme biosynthesis, leading to severe reactions to sunlight and significant impacts on patients' quality of life [8][9] - Current treatment options are limited, with only one FDA-approved therapy available, highlighting the need for new therapeutic options like bitopertin [8][9]

Core Viewpoint - Disc Medicine, Inc. is preparing to discuss feedback from the FDA regarding its investigational drug bitopertin for treating erythropoietic protoporphyria (EPP) in a conference call scheduled for January 21, 2025 [1]. Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases, aiming to create first-in-class therapeutic candidates targeting heme biosynthesis and iron homeostasis [6]. Product Information - Bitopertin is an investigational, orally administered inhibitor of glycine transporter 1 (GlyT1), designed to modulate heme biosynthesis and support erythropoiesis [3]. - The drug is being developed as a potential treatment for various hematologic diseases, including EPP, and has undergone multiple clinical trials, including the Phase 2 BEACON trial and the Phase 2 AURORA trial [3][4]. Disease Context - Erythropoietic protoporphyria (EPP) is a rare and debilitating disease caused by mutations affecting heme biosynthesis, leading to severe reactions to sunlight and potential liver complications [5]. - Current treatment options are limited, with only one FDA-approved therapy available, highlighting the significant unmet medical need in this area [5].

WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effective January 16, 2025. The inducement award is comprised of (i) an option to purchase 35,000 shares of Disc's common stock, at an exercise price equal to the closi ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory study designInitial data from an ongoing phase 2 study of DISC-0974 (anti-hemojuvelin antibody) in anemia of myelofibrosis (MF) expected H2 2025 Data from higher doses and multiple dose cohorts of a phase 1b study of DISC-0974 in anemia of chronic kidney disease (CKD) expected H2 2025Initiation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 Par Value IRON The Nasdaq Global Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _ ...

Exhibit 99.1 Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update • Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing data • Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society ...

Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half 2026Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the ...